Dianthus Therapeutics
DNTH
52 hedge funds and large institutions have $23.6M invested in Dianthus Therapeutics in 2023 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 13 closing their positions.
95% more capital inflows, than outflows
Capital inflows: $11.6M | Capital outflows: $5.94M
33% more call options, than puts
Call options by funds: $12K | Put options by funds: $9K
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
2.75% more ownership
Funds ownership: 46.21% → 48.96% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
2% less funds holding
Funds holding: 53 → 52 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$4.19M |
| 2 |
LPC
Lion Point Capital
New York
|
+$3.15M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.52M |
| 4 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$996K |
| 5 |
TCW Group
Los Angeles,
California
|
+$519K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP IV
Boston,
Massachusetts
|
-$2.67M |
| 2 |
Deep Track Capital
Greenwich,
Connecticut
|
-$1.19M |
| 3 |
Millennium Management
New York
|
-$914K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$343K |
| 5 |
Integral Health Asset Management
New York
|
-$164K |
DNTH Hedge Fund Activity: Q1 2023 in Review
52 of the 6,287 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q1 2023, worth a combined $23.6M — up 113% from $11.1M a quarter earlier.
Fund positioning in DNTH was balanced in Q1 2023: 13 funds opened new positions, 13 closed out, 11 added to existing stakes and 10 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $4.19M. The largest seller was TRV GP IV, exiting entirely with an estimated $2.67M sold.
- 52 institutional investors held Dianthus Therapeutics (DNTH) as of Q1 2023, down from 53 in Q4 2022.
- Funds reported $23.6M of Dianthus Therapeutics stock for Q1 2023, up 113% quarter-over-quarter.
- 13 funds opened new Dianthus Therapeutics positions in Q1 2023 and 13 closed out, a net change of 0 holders.
- The largest Dianthus Therapeutics buyer in Q1 2023 was Tang Capital Management, an estimated $4.19M added.
- The largest Dianthus Therapeutics seller in Q1 2023 was TRV GP IV, an estimated $2.67M sold.
Based on aggregated 13F filings for Q1 2023.